Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALNY's Cash to Debt is ranked higher than
91% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. ALNY: No Debt )
ALNY' s 10-Year Cash to Debt Range
Min: 6.39   Max: No Debt
Current: No Debt

Equity to Asset 0.87
ALNY's Equity to Asset is ranked higher than
90% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ALNY: 0.87 )
ALNY' s 10-Year Equity to Asset Range
Min: -0.76   Max: 0.87
Current: 0.87

-0.76
0.87
Interest Coverage No Debt
ALNY's Interest Coverage is ranked higher than
66% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: No Debt )
ALNY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 34.79
M-Score: 3.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -800.97
ALNY's Operating margin (%) is ranked higher than
59% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. ALNY: -800.97 )
ALNY' s 10-Year Operating margin (%) Range
Min: -14236.93   Max: -28.95
Current: -800.97

-14236.93
-28.95
Net-margin (%) -712.79
ALNY's Net-margin (%) is ranked higher than
60% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. ALNY: -712.79 )
ALNY' s 10-Year Net-margin (%) Range
Min: -14223.3   Max: -27.3
Current: -712.79

-14223.3
-27.3
ROE (%) -44.96
ALNY's ROE (%) is ranked higher than
70% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. ALNY: -44.96 )
ALNY' s 10-Year ROE (%) Range
Min: -336.03   Max: -13.08
Current: -44.96

-336.03
-13.08
ROA (%) -39.18
ALNY's ROA (%) is ranked higher than
69% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. ALNY: -39.18 )
ALNY' s 10-Year ROA (%) Range
Min: -97.61   Max: -5.01
Current: -39.18

-97.61
-5.01
ROC (Joel Greenblatt) (%) -2257.97
ALNY's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. ALNY: -2257.97 )
ALNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2120.98   Max: -168.68
Current: -2257.97

-2120.98
-168.68
Revenue Growth (3Y)(%) -29.60
ALNY's Revenue Growth (3Y)(%) is ranked higher than
65% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. ALNY: -29.60 )
ALNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 108
Current: -29.6

0
108
EBITDA Growth (3Y)(%) 65.40
ALNY's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. ALNY: 65.40 )
ALNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.8   Max: 65.4
Current: 65.4

-64.8
65.4
EPS Growth (3Y)(%) 52.80
ALNY's EPS Growth (3Y)(%) is ranked higher than
96% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ALNY: 52.80 )
ALNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.7   Max: 52.8
Current: 52.8

-66.7
52.8
» ALNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ALNY Guru Trades in Q1 2014

George Soros 3,092 sh (New)
Jim Simons 158,700 sh (New)
Steven Cohen 140,522 sh (+209.28%)
Vanguard Health Care Fund 4,524,800 sh (+10.22%)
Columbia Wanger 902,764 sh (-52.73%)
» More
Q2 2014

ALNY Guru Trades in Q2 2014

Vanguard Health Care Fund 4,973,900 sh (+9.93%)
George Soros Sold Out
Jim Simons Sold Out
Columbia Wanger 784,500 sh (-13.10%)
» More
Q3 2014

ALNY Guru Trades in Q3 2014

Steven Cohen 12,100 sh (New)
Vanguard Health Care Fund 5,277,100 sh (+6.10%)
Pioneer Investments 324,287 sh (unchged)
Columbia Wanger 554,000 sh (-29.38%)
» More
Q4 2014

ALNY Guru Trades in Q4 2014

Bill Frels 2,200 sh (New)
John Griffin 430,000 sh (New)
Paul Tudor Jones 3,540 sh (New)
Pioneer Investments 483,213 sh (+49.01%)
Steven Cohen Sold Out
Vanguard Health Care Fund 5,030,100 sh (-4.68%)
Columbia Wanger 477,700 sh (-13.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 23.64
ALNY's Forward P/E is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALNY: 23.64 )
N/A
P/B 8.70
ALNY's P/B is ranked higher than
61% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. ALNY: 8.70 )
ALNY' s 10-Year P/B Range
Min: 1.58   Max: 21.38
Current: 8.7

1.58
21.38
P/S 154.60
ALNY's P/S is ranked higher than
54% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. ALNY: 154.60 )
ALNY' s 10-Year P/S Range
Min: 3.09   Max: 189.72
Current: 154.6

3.09
189.72
EV-to-EBIT -19.80
ALNY's EV-to-EBIT is ranked higher than
67% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALNY: -19.80 )
ALNY' s 10-Year EV-to-EBIT Range
Min: -58.7   Max: 0.6
Current: -19.8

-58.7
0.6
Current Ratio 7.83
ALNY's Current Ratio is ranked higher than
84% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. ALNY: 7.83 )
ALNY' s 10-Year Current Ratio Range
Min: 1.88   Max: 9.72
Current: 7.83

1.88
9.72
Quick Ratio 7.83
ALNY's Quick Ratio is ranked higher than
84% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ALNY: 7.83 )
ALNY' s 10-Year Quick Ratio Range
Min: 1.88   Max: 9.72
Current: 7.83

1.88
9.72
Days Sales Outstanding 288.31
ALNY's Days Sales Outstanding is ranked higher than
68% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. ALNY: 288.31 )
ALNY' s 10-Year Days Sales Outstanding Range
Min: 0.57   Max: 288.31
Current: 288.31

0.57
288.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.70
ALNY's Price/Net Cash is ranked higher than
73% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. ALNY: 14.70 )
ALNY' s 10-Year Price/Net Cash Range
Min: 3.86   Max: 42.87
Current: 14.7

3.86
42.87
Price/Net Current Asset Value 13.90
ALNY's Price/Net Current Asset Value is ranked higher than
71% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. ALNY: 13.90 )
ALNY' s 10-Year Price/Net Current Asset Value Range
Min: 3.75   Max: 39.45
Current: 13.9

3.75
39.45
Price/Tangible Book 8.60
ALNY's Price/Tangible Book is ranked higher than
66% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. ALNY: 8.60 )
ALNY' s 10-Year Price/Tangible Book Range
Min: 2.64   Max: 15.17
Current: 8.6

2.64
15.17
Price/Median PS Value 7.70
ALNY's Price/Median PS Value is ranked higher than
63% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ALNY: 7.70 )
ALNY' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 7.06
Current: 7.7

0.2
7.06
Earnings Yield (Greenblatt) -5.20
ALNY's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ALNY: -5.20 )
ALNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6   Max: 1781.6
Current: -5.2

-6
1781.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DUL.Germany,
Alnylam Pharmaceuticals Inc was originally incorporated in Delaware under the name Alnylam Holding Co. on May 8, 2003. It is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The Company's research and development is focused primarily on use of its proprietary N-acetylgalactosamine, or GalNAc-conjugate for delivery of small interfering RNAs, or "siRNAs" — the molecules that mediate RNAi — toward liver-expressed genes involved in the cause or pathway of human diseases. It is also focused on clinical indications where there are high unmet medical needs, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval and commercialization. The Company operates in a single reporting segment, the discovery, development and commercialization of RNAi therapeutics. Its competitors include Takeda, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando Pharmaceuticals, Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence Therapeutics plc, Tekmira, Sylentis, S.A.U., or Sylentis, Dicerna Pharmaceuticals, Inc. and Arcturus Therapeutics, among others. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.
» More Articles for ALNY

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
comment on ALNY Mar 09 2013 
comment on ALNY Mar 02 2013 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CEO Buys Highlight: VITC, CTFO, RPM, EFC, ALNY Oct 17 2011 
Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 06 2009 
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2008 Financial Results Feb 17 2009 


More From Other Websites
Infinity Pharmaceuticals Exercises Duvelisib Royalty Option - Analyst Blog Apr 01 2015
Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog Mar 30 2015
Biotech “bubble” popped, time to buy again? Mar 27 2015
Alnylam Announces Positive Data from Natural History Study - Analyst Blog Mar 16 2015
Alnylam Presents Results from Natural History Study of Patients with Familial Amyloidotic... Mar 15 2015
Alnylam Presents Results from Natural History Study of Patients with Familial Amyloidotic... Mar 15 2015
Alnylam to Webcast Presentation at 22nd Annual Future Leaders in the Biotech Industry Conference Mar 13 2015
Alnylam to Webcast Presentation at 22nd Annual Future Leaders in the Biotech Industry Conference Mar 13 2015
Alnylam (ALNY) Shares March Higher, Can It Continue? - Tale of the Tape Mar 13 2015
Vanda Down after Candidate Disappoints in Phase II Study - Analyst Blog Mar 09 2015
Alnylam to Webcast Presentation at Barclays Global Healthcare Conference Mar 05 2015
Alnylam to Webcast Presentation at Barclays Global Healthcare Conference Mar 05 2015
Coverage initiated on Alnylam Pharma by Barclays Mar 04 2015
Mylan Beats on Q4 Earnings, 2015 Guidance Encouraging - Analyst Blog Mar 03 2015
Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog Mar 02 2015
QLT (QLTI) Reports Wider Year-over-Year Loss in Q4 - Analyst Blog Mar 02 2015
Endo (ENDP) Beats Q4 Earnings, Announces Divestments - Analyst Blog Mar 02 2015
Aegerion's Q4 Loss Narrows Y/Y, Ups Juxtapid Sales View - Analyst Blog Feb 27 2015
Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference Feb 25 2015
Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference Feb 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK